Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totaling 40,417 shares, a decrease of 57.5% from the March 31st total of 95,200 shares. Based on an average daily volume of 38,979 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.3% of the shares of the stock are sold short.
Hedge Funds Weigh In On Radiopharm Theranostics
A number of large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC bought a new stake in Radiopharm Theranostics in the 4th quarter worth $1,007,000. Virtu Financial LLC bought a new stake in Radiopharm Theranostics in the 4th quarter worth $76,000. Jane Street Group LLC bought a new stake in Radiopharm Theranostics in the 4th quarter worth $76,000. Marex Group plc bought a new stake in Radiopharm Theranostics in the 4th quarter worth $54,000. Finally, PNC Financial Services Group Inc. grew its holdings in Radiopharm Theranostics by 100.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company's stock worth $88,000 after acquiring an additional 8,000 shares during the last quarter.
Analyst Ratings Changes
RADX has been the subject of several research reports. Wall Street Zen lowered shares of Radiopharm Theranostics to a "strong sell" rating in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Radiopharm Theranostics in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Radiopharm Theranostics currently has an average rating of "Moderate Buy" and a consensus price target of $14.00.
Check Out Our Latest Analysis on Radiopharm Theranostics
Radiopharm Theranostics Price Performance
NASDAQ:RADX traded down $0.01 during trading hours on Friday, reaching $4.52. The company's stock had a trading volume of 17,665 shares, compared to its average volume of 41,358. The firm has a 50-day simple moving average of $4.69 and a 200-day simple moving average of $5.03. Radiopharm Theranostics has a 1 year low of $3.62 and a 1 year high of $16.25.
Radiopharm Theranostics (NASDAQ:RADX - Get Free Report) last issued its earnings results on Wednesday, January 28th. The company reported ($1.58) EPS for the quarter. The company had revenue of $0.46 million for the quarter. Research analysts anticipate that Radiopharm Theranostics will post -1.8 earnings per share for the current year.
Radiopharm Theranostics Company Profile
(
Get Free Report)
Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.
The company's research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Radiopharm Theranostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Radiopharm Theranostics wasn't on the list.
While Radiopharm Theranostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
